Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT AB on its combination with Coller Capital
Mandate

Vinge advises EQT AB on its combination with Coller Capital

January 22, 2026 Capital Markets and Public M&A M&A

Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.

This combination advances EQT’s ambition to build the most attractive private markets firm of scale, delivering industry-leading performance and solutions globally. Together, the two firms will be able to strengthen relationships and opportunities with institutional, private wealth and insurance-related clients while creating a deeper global EQT platform across private equity, infrastructure, real estate and secondaries.

The base consideration of USD 3.2 billion is to be funded through newly issued EQT ordinary shares, with up to USD 500 million in contingent consideration to be funded in cash.

Vinge's team primarily consisted of Sofie Bjärtun, Joel Magnusson, Maximilian Bengtsson (Capital Markets & Public M&A), Marcus Glader, Noelia Martinez (Regulatory), Mattias Schömer and Morgan Ödman (Corporate tax).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026